Research graph
References from TYK2 is essential for the therapeutic effect of IFN-α in Jak2V617F-induced murine myeloproliferative neoplasms. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2017 · External reference
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
10.1182/blood-2016-10-695940 · 2017 · External reference
Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia
10.3389/fonc.2020.636675 · 2021 · External reference
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
10.1007/s12185-022-03335-7 · 2022 · External reference
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
10.1182/blood-2008-03-143537 · 2008 · External reference
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
10.1200/jco.2009.23.6075 · 2009 · External reference
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
10.1002/ajh.23928 · 2015 · External reference
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
10.1179/102453309x12473408860587 · 2009 · External reference
Recombinant interferon-alpha for treatment of polycythaemia vera
10.1016/s0140-6736(88)92881-4 · 1988 · External reference
Treatment of essential thrombocythaemia by alpha 2a interferon
10.1016/s0140-6736(88)92625-6 · 1988 · External reference
Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial
2017 · External reference
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
10.1016/s2352-3026(19)30236-4 · 2020 · External reference
Interferons and their actions
10.1146/annurev.bi.56.070187.003455 · 1987 · External reference
The neglected role of type I interferon in the T-cell response: implications for its clinical use
10.1016/0167-5699(96)10027-x · 1996 · External reference
Antiproliferative properties of type I and type II interferon
10.3390/ph3040994 · 2010 · External reference
Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry
10.1089/107999002760274845 · 2002 · External reference
The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction
10.1038/366129a0 · 1993 · External reference
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway
10.1038/366166a0 · 1993 · External reference
Cytokine receptor signalling
10.1038/377591a0 · 1995 · External reference
Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA
10.1016/0092-8674(90)90738-z · 1990 · External reference
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
10.1126/science.8197455 · 1994 · External reference
Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster
10.1002/j.1460-2075.1995.tb00192.x · 1995 · External reference
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
10.1016/s0092-8674(00)81166-6 · 1998 · External reference
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
10.1016/s0092-8674(00)81288-x · 1996 · External reference
Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function
10.1016/s1074-7613(00)00055-8 · 2000 · External reference
Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation
10.4049/jimmunol.169.9.4707 · 2002 · External reference
Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth
10.1046/j.1365-2141.2003.04650.x · 2003 · External reference
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
10.1038/sj.leu.2405043 · 2008 · External reference
Loss of tyrosine kinase 2 does not affect the severity of Jak2V617F-induced murine myeloproliferative neoplasm
2017 · External reference
Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
10.1038/s41375-020-0880-3 · 2021 · External reference
Multifaceted activities of type I interferon are revealed by a receptor antagonist
10.1126/scisignal.2004998 · 2014 · External reference
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera
10.1182/blood-2012-05-432989 · 2013 · External reference
Ropeginterferon alfa-2b, a novel IFα-2b, induces high response rates with low toxicity in patients with polycythemia vera
10.1182/blood-2015-04-637280 · 2015 · External reference
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
10.1038/s41375-019-0638-y · 2020 · External reference
JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality
10.1182/blood.2020005563 · 2021 · External reference
Type I interferon: friend or foe?
10.1084/jem.20101664 · 2010 · External reference
A critical function for type I interferons in cancer immunoediting
10.1038/ni1213 · 2005 · External reference
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
10.4049/jimmunol.178.12.7540 · 2007 · External reference
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells
10.1074/jbc.m509516200 · 2006 · External reference
STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon-α2b peptide
10.1016/j.yexcr.2009.11.016 · 2010 · External reference
